Kidney Cancer Clinical Trial
Participant Reported Outcomes and Treatment Experiences in Kidney Cancer
Summary
The purpose of this observational study is to collect contemporary real-world treatment patterns, clinical outcomes, humanistic burden (including patient-reported disease-specific Health-related Quality of Life (HRQoL), and treatment- related adverse events (AEs) or adverse reactions (ARs) among Advanced Renal Cell Carcinoma (aRCC) patients initiating first-line systemic therapy.
Eligibility Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Cohort 1
Primary diagnosis of aRCC (advanced Renal Cell Carcinoma) or metastatic RCC
Medical history must be available from date of aRCC diagnosis
Initiated 1LOT between April 2018 - March 2020
Cohort 2:
Primary diagnosis of aRCC (not amenable to curative surgery or radiation therapy/ AJCC Stage III unresectable) or metastatic RCC (AJCC Stage IV).
Medical history must be available from date of aRCC diagnosis.
Initiate 1LOT.
Exclusion Criteria:
Currently enrolled in a clinical trial for treatment of aRCC
Any prior malignancy active within the previous 3 year, except for locally curable cancers that have been cured
Any prior systemic therapy for aRCC, with the exception of neoadjuvant or adjuvant therapy (Cohort 2 only)
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Morristown New Jersey, 07960, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.